Allecra Therapeutics today announced that summary data from the Phase 3 (ALLIUM) trial evaluating cefepime-enmetazobactam (FPE) compared to the first-line standard of care, piperacillin-tazobactam (PTZ), in complicated urinary tract infections (cUTI) are being presented at this week’s IDWeek 2020.
PRESS RELEASES & ARTICLES
STAY UPDATED
Allecra Therapeutics Announces Late-breaker Presentation of Phase 3 ALLIUM Trial with Cefepime-Enmetazobactam in cUTIs at IDWeek 2020
October 23, 2020
PDF
Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing
October 19, 2020
Topas Therapeutics GmbH today announced the successful closing of a €22 million (~$26 million) Series B financing round. New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas’ existing investors.
Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer
October 19, 2020
Topas Therapeutics GmbH today announced the appointment of Klaus Martin, Ph.D., as Chief Executive Officer. Effective August 1, 2020, Dr. Martin replaced Timm Jessen, Ph.D., who resigned for personal reasons. Dr. Jessen will remain with Topas in a consulting capacity to ensure a smooth transition.
Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris
December 18, 2019
PDFCrescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey
September 12, 2019
PDFImmatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies
August 28, 2019
PDFImmatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients
July 19, 2019
PDFImmatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers
April 09, 2019
PDFImmatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
February 26, 2019
PDFUS Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
January 03, 2019
PDFNature publication reports first-in-human trial for a personalized cancer immunotherapy
December 20, 2018
PDFOpsona Therapeutics to present results on Tomaralimab study at the 60th Annual Meeting of the American Society of Hematology (ASH)
October 25, 2018
PDFEMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million (USD 245 Million) Transaction.
September 13, 2018
PDFTopas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund
November 02, 2017
PDFImmatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
October 04, 2017
PDFCrescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards
June 16, 2017
PDF